The Indicator Test Neuropad in the Assessment of Small and Overall Nerve Fibre Dysfunction in Patients with Type 2 Diabetes: a Large Multicentre Study

C. Manes; N. Papanas; T. Exiara; N. Katsiki; S. Papantoniou; E. Kirlaki; S. Tsotoulidis; N. Kefalogiannis; E. Maltezos

doi:10.1055/s-0034-1367061

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2014; 122(03): 195-199
DOI: 10.1055/s-0034-1367061

Short Communication

The Indicator Test Neuropad in the Assessment of Small and Overall Nerve Fibre Dysfunction in Patients with Type 2 Diabetes: a Large Multicentre Study

Authors

C. Manes

¹Diabetes Centre, General Hospital “PAPAGEORGIOU”, Thessaloniki, Greece
N. Papanas

²Diabetes Clinic, 2 nd Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece
T. Exiara

¹Diabetes Centre, General Hospital “PAPAGEORGIOU”, Thessaloniki, Greece
N. Katsiki

³Second Propedeutic Department of Internal Medicine, Hippokration University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
S. Papantoniou

⁴Diabetes Clinic, First Department of Internal Medicine, General Hospital of Kavala, Greece
E. Kirlaki

⁵Diabetes Clinic, Venizelion Hospital, Heraklion, Crete, Greece
S. Tsotoulidis

⁶Health Centre, Kassandria, Halkidiki, Greece
N. Kefalogiannis

⁵Diabetes Clinic, Venizelion Hospital, Heraklion, Crete, Greece
E. Maltezos

²Diabetes Clinic, 2 nd Department of Internal Medicine, Democritus University of Thrace, Alexandroupolis, Greece

Abstract

We examined the diagnostic utility of the indicator test Neuropad in the assessment of overall and small fibre dysfunction in 1 010 patients with type 2 diabetes mellitus (T2DM) (608 men, mean age 63.9±10.3 years) from 5 diabetes clinics. Sudomotor function was diagnosed by the Neuropad^® test. Overall and small nerve fibre dysfunction was diagnosed through clinical examination and symptoms. Patients were divided into Groups A (441 patients with sudomotor dysfunction) and B (569 patients without sudomotor dysfunction). The former were older (p<0.05) and had longer T2DM duration (p<0.05) than the latter. For overall nerve fibre dysfunction, abnormal Neuropad defined as patchy/blue had 94.9% sensitivity, 70.2% specificity and 98.1% negative predictive value (NPV), while for small fibre dysfunction the corresponding values were 85.6%, 71.2% and 93.3%. For overall nerve fibre dysfunction, abnormal Neuropad defined as blue had 64% sensitivity, 96% specificity and 91% NPV, while for small fibre dysfunction the corresponding values were 52%, 96% and 85%. The odds ratios (ORs) of Neuropad patchy/blue for overall and for small fibre dysfunction were 43.7 and 14.7, respectively. The ORs of Neuropad blue for overall and for small fibre dysfunction were 45.7 and 24.9, respectively. In conclusion, Neuropad patchy/blue response exhibited better diagnostic performance both for overall and small nerve fibre dysfunction. Its very high NPV renders it an excellent screening tool primarily to exclude neuropathy in T2DM.

Key words

diabetes mellitus - diabetic neuropathy - Neuropad - small fibre dysfunction - sudomotor dysfunction.

Volltext

Referenzen

References
1 American Diabetes Association . Standards of medical care in diabetes – 2013. Diabetes Care 2013; 36 (Suppl. 01) S11-S66
2 Abbott CA, Vileikyte L, Williamson S et al. Multicenter study of the incidence of and predictive risk factors for diabetic neuropathic foot ulceration. Diabetes Care 1998; 21: 1071-1075
3 Abbott CA, Carrington AL, Ashe H et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med 2002; 19: 377-384
4 Antonoglou C, Papanas N, Maltezos E. Lipid-lowering therapy in the diabetic foot: seeing the whole iceberg and not just the tip. Curr Vasc Pharmacol 2012; [Epub ahead of print]
5 Apelqvist J, Bakker K, van Houtum WH et al. International Working Group on the Diabetic Foot (IWGDF) Editorial Board . Practical guidelines on the management and prevention of the diabetic foot: based upon the International Consensus on the Diabetic Foot (2007) Prepared by the International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2008; 24 (Suppl. 01) S181-S187
6 Bierhaus A, Nawroth PP. Critical evaluation of mouse models used to study pain and loss of pain perception in diabetic neuropathy. Exp Clin Endocrinol Diabetes 2012; 120: 188-190
7 Boulton AJM, Kirsner RS, Vileikyte L. Neuropathic diabetic foot ulcers. N Engl J Med 2004; 351: 48-55
8 Boulton AJM. The diabetic foot: from art to science. The 18^th Camillo Golgi lecture. Diabetologia 2004; 47: 1343-1353
9 Calvet JH, Dupin J, Winiecki H et al. Assessment of small fiber neuropathy through a quick, simple and non invasive method in a German diabetes outpatient clinic. Exp Clin Endocrinol Diabetes 2013; 121: 80-83
10 Chin MH, Auerbach SB, Cook S et al. Quality of diabetes care in community health centers. Am J Public Health 2000; 90: 431-434
11 De Berardis G, Pellegrini F, Franciosi M et al. The QuED Study Group-Quality of Care and Outcomes in Type 2 Diabetes. J Diabet Complications 2005; 19: 319-327
12 Eaton S, Tesfaye S. Clinical manifestations and measurement of neuropathy. Diabetes Rev 1999; 7: 312-325
13 Forsblom CM, Sane T, Groop PH et al. Risk factors for mortality in type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DR4. Diabetologia 1998; 4: 1253-1262
14 Kamenov ZA, Petrova JJ, Christov VG. Diagnosis of diabetic neuropathy using simple somatic and a new autonomic (Neuropad) tests in the clinical practice. Exp Clin Endocrinol Diabetes 2010; 118: 226-233
15 Liatis S, Marinou K, Tentolouris N et al. Usefulness of a new indicator test for the diagnosis of peripheral and autonomic neuropathy in patients with diabetes mellitus. Diabet Med 2007; 24: 1375-1380
16 Low VA, Sandroni P, Fealey RD et al. Detection of small-fiber neuropathy by sudomotor testing. Muscle Nerve 2006; 34: 57-61
17 Manes C, Papazoglou N, Sossidou E et al. Prevalence of diabetic neuropathy and foot ulceration identification of potential risk factors – A population based study. Wounds 2002; 14: 11-15
18 Martina ISJ, van Koningsveld R, Schmitz PIM et al. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry 1998; 65: 743-747
19 Mondelli M, Aretini A, Baldasseroni A. Distal symmetric polyneuropathy in diabetes. Differences between patients with and without neuropathic pain. Exp Clin Endocrinol Diabetes 2012; 120: 45-50
20 Papanas N, Papatheodorou K, Christakidis D et al. Evaluation of a new indicator test for sudomotor function (Neuropad) in the diagnosis of peripheral neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2005; 113: 195-198
21 Papanas N, Papatheodorou K, Papazoglou D et al. Reproducibility of the new indicator test for sudomotor function (Neuropad) in patients with type 2 diabetes mellitus: short communication. Exp Clin Endocrinol Diabetes 2005; 113: 577-581
2 Papanas N, Papatheodorou K, Papazoglou D et al. The new indicator test (Neuropad): a valuable diagnostic tool for small-fiber impairment in patients with type 2 diabetes. Diabetes Educ 2007; 33: 257-262
23 Papanas N, Giassakis G, Papatheodorou K et al. Use of the new indicator test (Neuropad) for the assessment of the staged severity of neuropathy in type 2 diabetic patients. Exp Clin Endocrinol Diabetes 2007; 115: 58-61
24 Papanas N, Papatheodorou K, Papazoglou D et al. An insertion/deletion polymorphism in the alpha2B adrenoceptor gene is associated with peripheral neuropathy in patients with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2007; 115: 327-330
25 Papanas N, Maltezos E. The diabetic foot: established and emerging treatments. Acta Clin Belg 2007; 62: 230-238
26 Papanas N, Papatheodorou K, Papazoglou D et al. A comparison of the new indicator test for sudomotor function (Neuropad) with the vibration perception threshold and the clinical examination in the diagnosis of peripheral neuropathy in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 2008; 116: 135-138
27 Papanas N, Papatheodorou K, Papazoglou D et al. A prospective study on the use of the indicator test Neuropad^® for the early diagnosis of peripheral neuropathy in type 2 diabetes. Exp Clin Endocrinol Diabetes 2011; 119: 122-125
28 Papanas N, Paschos P, Papazoglou D et al. Accuracy of the Neuropad test for the diagnosis of distal symmetric polyneuropathy in type 2 diabetes. Diabetes Care 2011; 34: 1378-1382
29 Papanas N, Maltezos E, Edmonds M. Salvation of the diabetic foot: still a quest for the Holy Grail?. Vasa 2011; 40: 267-269
30 Papanas N, Katsiki N, Papatheodorou K et al. Peripheral neuropathy is associated with increased serum levels of uric acid in type 2 diabetes mellitus. Angiology 2011; 62: 291-295
31 Papanas N, Ziegler D. New diagnostic tests for diabetic distal symmetric polyneuropathy. J Diabetes Complications 2011; 25: 44-51
32 Papanas N, Boulton AJ, Malik RA et al. A simple new non-invasive sweat indicator test for the diagnosis of diabetic neuropathy. Diabet Med 2013; 30: 525-534
33 Quattrini C, Jeziorska M, Malik R. Small fiber neuropathy in diabetes: clinical consequences and assessment. Int J Low Extrem Wounds 2004; 3: 16-21
34 Quattrini C, Jeziorska M, Tavakoli M et al. The Neuropad test: a visual indicator test for human diabetic neuropathy. Diabetologia 2008; 51: 1046-1050
35 Shaw JE, Zimmet PZ, Gries FA et al. Epidemiology of diabetic neuropathy. In: Gries FA, Cameron NE, Low PA, Ziegler D. (Eds.). Textbook of Diabetic Neuropathy. Stuttgart: Thieme Verlag; 2003: 64-82
36 Spallone V, Morganti R, Siampli M et al. Neuropad as a diagnostic tool for diabetic autonomic and sensorimotor neuropathy. Diabet Med 2009; 26: 686-692
37 Tentolouris N, Achtsidis V, Marinou K et al. Evaluation of the self-administered indicator plaster Neuropad for the diagnosis of neuropathy in diabetes. Diabetes Care 2008; 31: 236-237
38 Tesfaye S, Boulton AJ, Dyck PJ et al. Toronto Diabetic Neuropathy Expert Group . Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285-2293
39 Várkonyi T, Putz Z, Keresztes K et al. Current options and perspectives in the treatment of diabetic neuropathy. Curr Pharm Des 2013; 19: 4981-5007
40 Veves A, Young MJ, Manes C et al. Differences in peripheral and autonomic nerve function measurements in painful and painless neuropathy: a clinical study. Diabetes Care 1994; 17: 1200-1202
41 Vinik AI, Erbas T, Stansberry KB et al. Small fiber neuropathy and neurovascular disturbances in diabetes mellitus. Exp Clin Endocrinol Diabetes 2001; 109 (Suppl. 02) S451-S473
42 Young MJ, Boulton AJM, Macleod AF et al. A multicenter study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993; 36: 150-154
43 Ziegler D, Papanas N, Roden M. GDC Study Group . Neuropad: evaluation of three cut-off points of sudomotor dysfunction for early detection of polyneuropathy in recently diagnosed diabetes. Diabet Med 2011; 28: 1412-1415
44 Ziegler D, Papanas N, Rathmann W et al. KORA Study Group . Evaluation of the Neuropad sudomotor function test as a screening tool for polyneuropathy in the elderly population with diabetes and pre-diabetes: the KORA F4 survey. Diabetes Metab Res Rev 2012; 28: 692-697